Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
工程合成免疫细胞具有模块化前哨和 T1D 治疗功能
基本信息
- 批准号:10436126
- 负责人:
- 金额:$ 83.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AdhesionsAntigensAutoimmune DiseasesBeta CellCD4 Positive T LymphocytesCell TherapyCellsCytotoxic T-LymphocytesDiseaseEngineeringEvaluationGoalsHomeIL2RA geneImmuneImmunosuppressionImmunotherapeutic agentIn VitroInflammatoryInsulin-Dependent Diabetes MellitusInterleukin-10Islet CellIslets of LangerhansKidneyLinkMalignant NeoplasmsModelingMusOutputPatientsProductionProteinsReportingSentinelSystemTestingTherapeuticTissuesUrsidae Familyautoreactive T cellcapsulecell typecellular engineeringcytokinedesign-build-testearly onsetflexibilityhuman pluripotent stem cellimmunoengineeringimplantationin vivoinnovationinsulin dependent diabetes mellitus onsetisletislet stem cellsnew technologynovelnovel strategiesprotective factorsreceptorresidenceresponsesensorsynthetic constructtrafficking
项目摘要
PROJECT SUMMARY
Our long-term goal is to engineer therapeutic immune cells that can report on and treat early-stage type 1
diabetes (T1D). Ideally, these cells should home to islets, detect and integrate multi-factor signatures of early-
stage disease and, in response, induce localized immunosuppression to block destruction of beta cells. Although
this seems like an extraordinarily difficult multi-level challenge, the remarkable progress in engineering immune
cells to recognize and kill cancer has generated a broad set of new technologies and approaches that could be
brought to bear on cell-based therapies for T1D. Here we propose to repurpose, redirect, and extend cell
engineering approaches to construct synthetic immune cells (CD4+ T cells) capable of sensing and treating
early-stage autoimmune disorders like T1D. Given the multiple challenges in achieving this goal, we propose to
take a modular approach – we have broken up what an ideal anti-T1D cell therapy would have to achieve into
three distinct subtasks. Our focus will be on independently engineering and validating cell circuit modules that
can achieve these subtasks, which can then be linked together in multiple combinations to develop options for a
full therapy. These modular objectives are outlined in our specific aims:
Aim 1. ISLET SENSING/TARGETING | Engineer synthetic immune cell sentinels that recognize and
establish residence/activity in the pancreas/islets. Sensors of pancreatic/islet specific antigens; islet
restricted activation using synNotch receptors; and islet trafficking via synthetic adhesion proteins.
Aim 2. AUTOIMMUNE DISEASE SENSING | Engineer synthetic immune cells that sense and report on
local immune perturbations associated with T1D onset. Engineer sensors that detect presence of
autoreactive T cells and elevated local levels of specific inflammatory cytokines
Aim 3. IMMUNO-SUPPRESSIVE OUTPUT: Engineer therapeutic cells that protect islets by inducing local
immunosuppressive outputs in response to disease sensing. Engineer output responses encompassing
induced local production of suppressive cytokines (IL10, TGFb), inflammatory cytokine sinks (CD25), and other
beta-cell protective factors. We will test multiple configurations of linking the disease sensing circuits from Aims
1 and 2 to the suppressive outputs from Aim 3.
To develop innovative cell engineering platforms for treating T1D, we propose to focus on human pluripotent
stem cell (hPSC)-derived islets as a highly flexible system in which to evaluate the immunoprotective function.
hPSC-cells can be readily generated and genetically modified to add convenient model antigens for sensing or
killing, allowing for the rapid design-build-test iterative cycles for the circuit modules described above (i.e.,
making each aim non-dependent on the others). hPSC islets can also be used to assess immunoprotective
responses against a variety of islet-targeted cytotoxic T cells, both in vitro and in vivo (implantation in mouse
kidney capsule), making this platform ideal for proof-of-principle evaluation and cell circuit optimization.
项目摘要
我们的长期目标是设计治疗性免疫细胞,可以报告和治疗早期1型
糖尿病(T1 D)。理想情况下,这些细胞应该归巢于胰岛,检测并整合早期胰岛素的多因素特征。
分期疾病,并作为响应诱导局部免疫抑制以阻断β细胞破坏。虽然
这似乎是一个非常困难的多层次挑战,工程免疫的显着进展,
细胞识别和杀死癌症已经产生了一系列广泛的新技术和方法,
用于T1 D的细胞疗法。在这里,我们建议重新调整、重定向和扩展单元格
构建能够感测和治疗的合成免疫细胞(CD 4 + T细胞)的工程方法
早期自身免疫性疾病比如T1 D鉴于在实现这一目标方面面临的多重挑战,我们建议
采用模块化方法-我们已经将理想的抗T1 D细胞疗法必须实现的目标分解为
三个不同的子任务。我们的重点将是独立设计和验证电池电路模块,
可以实现这些子任务,然后可以将这些子任务以多种组合方式链接在一起,以开发
全套治疗这些模块化目标在我们的具体目标中概述:
目标1.胰岛传感/靶向|设计合成免疫细胞哨兵,
在胰腺/胰岛中建立驻留/活动。胰腺/胰岛特异性抗原传感器;胰岛
使用synNotch受体的限制性激活;以及通过合成粘附蛋白的胰岛运输。
目标2.自身免疫疾病感知|设计合成免疫细胞,
与T1 D发作相关的局部免疫扰动。工程传感器,检测存在的
自身反应性T细胞和局部特异性炎症细胞因子水平升高
目标3.免疫抑制输出:工程治疗细胞,通过诱导局部
免疫抑制输出响应于疾病感测。工程师输出响应,包括
诱导局部产生抑制性细胞因子(IL 10、TGF β)、炎性细胞因子汇(CD 25)和其他
β细胞保护因子。我们将测试连接Aims疾病感知电路的多种配置
目标1和2的抑制性输出与目标3的抑制性输出之间的关系。
为了开发用于治疗T1 D的创新细胞工程平台,我们建议将重点放在人类多能干细胞上。
干细胞(hPSC)衍生的胰岛作为一个高度灵活的系统,其中评估免疫保护功能。
hPSC-细胞可以容易地产生和遗传修饰以添加方便的模型抗原用于感测或免疫原性。
消除,允许上述电路模块的快速设计-构建-测试迭代循环(即,
使每个目标不依赖于其他目标)。hPSC胰岛也可用于评估免疫保护性
在体外和体内(在小鼠中的植入)针对多种胰岛靶向的细胞毒性T细胞的应答
肾胶囊),使该平台成为原理验证评估和电池电路优化的理想选择。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WENDELL A LIM其他文献
WENDELL A LIM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WENDELL A LIM', 18)}}的其他基金
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
工程合成免疫细胞具有模块化前哨和 T1D 治疗功能
- 批准号:
10594512 - 财政年份:2022
- 资助金额:
$ 83.08万 - 项目类别:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
通过设计 NOT 门改善 CAR T 细胞的脱靶毒性
- 批准号:
10657356 - 财政年份:2022
- 资助金额:
$ 83.08万 - 项目类别:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
通过设计 NOT 门改善 CAR T 细胞的脱靶毒性
- 批准号:
10362126 - 财政年份:2022
- 资助金额:
$ 83.08万 - 项目类别:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
识别肿瘤生态系统:整合基质信号和癌抗原信号,实现CAR T细胞对实体瘤的精准识别
- 批准号:
10094815 - 财政年份:2020
- 资助金额:
$ 83.08万 - 项目类别:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
识别肿瘤生态系统:整合基质信号和癌抗原信号,实现CAR T细胞对实体瘤的精准识别
- 批准号:
10559489 - 财政年份:2020
- 资助金额:
$ 83.08万 - 项目类别:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
识别肿瘤生态系统:整合基质信号和癌抗原信号,实现CAR T细胞对实体瘤的精准识别
- 批准号:
10310406 - 财政年份:2020
- 资助金额:
$ 83.08万 - 项目类别:
Engineering synthetic helper cells that autonomously deliver orthogonal IL-2 to selectively promote therapeutic T cell proliferation in tumors
工程合成辅助细胞可自主递送正交 IL-2 以选择性促进肿瘤中治疗性 T 细胞增殖
- 批准号:
10285941 - 财政年份:2019
- 资助金额:
$ 83.08万 - 项目类别:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
加州大学旧金山分校合成免疫学中心:重新编程免疫系统以对抗癌症的工具
- 批准号:
10598367 - 财政年份:2019
- 资助金额:
$ 83.08万 - 项目类别:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
加州大学旧金山分校合成免疫学中心:重新编程免疫系统以对抗癌症的工具
- 批准号:
10598362 - 财政年份:2019
- 资助金额:
$ 83.08万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 83.08万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 83.08万 - 项目类别: